{
    "nctId": "NCT05555706",
    "briefTitle": "Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer",
    "officialTitle": "A Phase II/III Study to Evaluate the Efficacy and Safety of B013 in Combination With Nab-Paclitaxel in First-line Treatment for Patients With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer (TNBC)",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 450,
    "primaryOutcomeMeasure": "Objective response rate (ORR)(phase \u2161)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Women or men aged 18 -75 years\n2. Locally advanced or metastatic triple negative breast cancer (TNBC)\n3. No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC\n4. ECOG performance status of 0 or 1\n5. Patient must have measurable or evaluable disease as defined by RECIST v1.1. Measurable lesions will be confirmed by radiographic imaging (CT or MRI)\n\nExclusion Criteria:\n\n1. Previous treatment is eligible.\n2. Spinal cord compression not definitively treated with surgery and/or radiation prior to study entry\n3. Known central nervous system (CNS) disease\n4. Uncontrolled pleural effusion, pericardial effusion, or ascites Patients\n5. Uncontrolled tumor-related pain prior to study entry\n6. The patient has a history of another malignancy within 5 years prior to study entry, except adequately treated non-melanotic skin cancer, carcinoma in situ of the cervix or Papillary carcinoma of the thyroid\n7. Pregnancy or lactation",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}